Phase 3 Study of AL001 in Individuals with or at risk for FTD

• Research type

  Research Study

• Full title

  A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

• IRAS ID

  1003370

• Contact name

  Catherine Mummery

• Contact email

  cath.mummery@nhs.net

• Eudract number

  2019-004066-18

• Clinicaltrials.gov Identifier

  NCT04374136

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  20/YH/0269

• Date of REC Opinion

  3 Dec 2020

• REC opinion

  Further Information Favourable Opinion